Immunogenicity of Current and New Therapies for Hemophilia A

Immunogenicity of Current and New Therapies for Hemophilia A

Anti-drug antibody (ADA) development is a significant complication in the treatment of several conditions. For decades, the mainstay of hemophilia A treatment was the replacement of deficient coagulation factor VIII (FVIII) to restore hemostasis, control, and prevent bleeding events. Recently, new p...

Full description

Bibliographic Details
Main Authors: Alessandra N. L. Prezotti, Jéssica O. Frade-Guanaes, Gabriela G. Yamaguti-Hayakawa, Margareth C. Ozelo
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Pharmaceuticals
Subjects:
hemophilia
factor VIII
blood coagulation factors
inhibitors
immunogenicity
plasma-derived factor VIII
Online Access:https://www.mdpi.com/1424-8247/15/8/911

Internet

https://www.mdpi.com/1424-8247/15/8/911

Similar Items